<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31049" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Vein Obstruction</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Packer</surname>
            <given-names>Corrine F.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bickel</surname>
            <given-names>Scott</given-names>
          </name>
          <aff>Resurrection Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dattilo</surname>
            <given-names>Jeffery B.</given-names>
          </name>
          <aff>University of Tennessee</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Corrine Packer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Scott Bickel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeffery Dattilo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31049.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Venous obstruction is partial or complete occlusion of the lumen of a vein. It can lead to decreased venous flow and increased blood pooling. Venous stasis results in increased viscosity and the formation of microthrombi which may be caused by anything that slows or obstructs the flow of venous blood. One of the most common causes is damage to the intima of the endothelium secondary to intrinsic or external trauma. The most common medically relevant type of venous thrombosis is deep vein thrombosis of the lower extremities. Another less common but important presentation of venous obstruction is primary thrombosis of the portal vein. This activity describes the risk factors, evaluation, and management of venous obstruction and highlights the role of the interprofessional team in enhancing care delivery for affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of venous obstruction.</p></list-item><list-item><p>Describe the common presentation of venous obstruction.</p></list-item><list-item><p>Describe the management of venous obstruction.</p></list-item><list-item><p>Explain the importance of improving care coordination, with particular emphasis on communication between interprofessional medical teams, to enhance prompt and thorough delivery of care to patients with venous obstruction.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31049&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31049">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31049.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The circulatory system can be divided based on blood vessels types. The venous system comprises blood vessels which carry blood from tissue and organs allowing a return to the heart. The majority of veins carry deoxygenated blood with the exceptions of the umbilical vein which is&#x000a0;patent during fetal development, growth and closes after birth and the pulmonary vein. The 3 layers which&#x000a0;constitute the structure of a vein are the outer connective tissue layer (tunica adventitia or tunica externa); the middle smooth muscle layer (tunica media); and the inner endothelial cell layer (tunica intima). The middle, smooth muscle layer is less muscular in veins compared to arteries allowing for increased capacitance; however, valves are needed to provide unidirectional flow.</p>
        <p>Venous obstruction is partial or complete occlusion of the lumen and can be related to decreased flow and increased pooling. The most commonly seen is a deep vein thrombosis in the lower extremities &#x02014; venous stasis results in&#x000a0;increased viscosity and the formation of microthrombi. This is due to any factor which slows or obstructs the flow of venous blood. One of the most common causes is endothelial (intimal) damage secondary to intrinsic or secondary to external trauma. In a hypercoagulable state, a biochemical imbalance between procoagulant and anticoagulant factors occur. Chronic venous insufficiency is a manifestation of decreased vein wall contractility and vein valve dysfunction.</p>
        <p>Other areas affected by venous obstruction include portal vein obstruction which is primary thrombosis of the portal vein.</p>
      </sec>
      <sec id="article-31049.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Venous thromboembolism (VTE) is a multifactorial disorder which can be due to inherited or acquired risk factors.</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Inherited: </italic>Factor V Leiden is the most common condition. This condition might not cause blood clots on its own, only when combined with 1 or more other risk factors.<xref ref-type="bibr" rid="article-31049.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Prolonged immobilization:</italic> Decreased activity of the soleus pump increase the risk of stasis and lead to thromboembolism formation. This is seen&#x000a0;after prolonged bed rest, long plane flights, and&#x000a0;intensive care unite (ICU) hospitalizations.</p>
          </list-item>
          <list-item>
            <p>Direct or indirect injury to veins or from surgical procedures can increase the risk of clot formation.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Pregnancy </italic>can increase the risk by 2 mechanisms: Increase hypercoagulability as the concentration of clotting factors are affected these include fibrinogen, which can rise 3-times its normal value, thrombin levels increase, and Protein S, an anticoagulant, decreases.<xref ref-type="bibr" rid="article-31049.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Birth control pills (oral contraceptives) or hormone replacement therapy:&#x000a0;</italic>Oral contraceptives cause significant increases in fibrinogen levels.<xref ref-type="bibr" rid="article-31049.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Obesity</italic>&#x000a0;has been shown to be associated with an increased risk of venous thromboembolism.<xref ref-type="bibr" rid="article-31049.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Smoking:</italic>&#x000a0;Factor XIII, which stabilizes fibrin clots, is increased in smokers and exposure to nicotine may also increase plasminogen activator inhibitor-1 (a major regulator of fibrinolysis). Quantitative exposure to passive smoke has been positively correlated with blood coagulation activity.<xref ref-type="bibr" rid="article-31049.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Cancer: </italic>Some forms of cancer increase substances&#x000a0;that cause blood to clot. Certain cancer treatments also increase the risk of blood clots.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Heart failure: </italic>Decreased function leads to increased venous pooling and increased stasis.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Inflammatory bowel diseases</italic>&#x000a0;including Crohn disease or ulcerative colitis increase the risk of deep vein thrombosis (DVT).</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31049.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Each year, there are about 4,000,000 surgical patients and 8,000,000 medical patients who&#x000a0;are hospitalized&#x000a0;in the United States at moderate or high risk for VTE.<xref ref-type="bibr" rid="article-31049.r5">[5]</xref>&#x000a0;In a global&#x000a0;cross-sectional study, a large proportion of hospitalized patients were also at moderate or high risk for VTE, more specifically, 42% of medical patients and 64% of surgical patients.<xref ref-type="bibr" rid="article-31049.r6">[6]</xref>&#x000a0;Among hospitalized medical patients, the 4 risk factors most predictive of VTE in the Intermountain Healthcare database were: (1) previous VTE, (2) bed rest, (3) peripherally inserted&#x000a0;central venous catheter, and 4) cancer.<xref ref-type="bibr" rid="article-31049.r7">[7]</xref>&#x000a0;Of particular importance is VTE in the outpatient setting. In a community study in Worcester, about three-fourths of patients developed VTE as outpatients. More than half had undergone surgery or had&#x000a0;been hospitalized&#x000a0;within the prior 3 months.<xref ref-type="bibr" rid="article-31049.r8">[8]</xref>&#x000a0;Cancer, severe infection, or congestive heart failure increased the likelihood of a poor outcome from VTE in the community setting.<xref ref-type="bibr" rid="article-31049.r9">[9]</xref>&#x000a0;In a population-based study in Norway, the incidence rate for all first VTE events was 1.43 per 1000 person-years. For DVT it was 0.93 per 1000 person-years with a 30-day case-fatality rate was 4.6% for DVT. &#x000a0;Incidence rates increased exponentially with age and were slightly higher in women than men.</p>
      </sec>
      <sec id="article-31049.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Venous thrombosis pathogenesis is based on the triad of Virchow proposed in 1865. The triad includes venous stasis, changes in the vessel wall,&#x000a0;and/or changes in the blood leading to a hypercoagulability state which can increase the risk of obstruction.<xref ref-type="bibr" rid="article-31049.r10">[10]</xref></p>
      </sec>
      <sec id="article-31049.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Venous obstruction is most commonly seen in the form of deep venous thrombosis (DVT). Patients present with unilateral or bilateral leg swelling after prolonged stasis, for example, plane travel or another long period of inactivity. Other symptoms include leg pain, which can occur in 50% of patients and is aggravated by dorsiflexion. Edema, if present, is one of the most specific symptoms of DVT. There is no correlation to the pain and tenderness to the size of the thrombus.</p>
        <p>Finding are usually confined to the affected limb. These include tenderness to the calf with a positive Homans sign which is a pain with passive dorsiflexion). Leg swelling of 2 centimeters or more in the affected limb is suggestive of DVT, and a positive D-dimer test shows the highest correlation to DVT.<xref ref-type="bibr" rid="article-31049.r11">[11]</xref></p>
        <p>Symptoms of portal vein thrombosis include right upper quadrant pain, nausea, and/or fever. Patients may have progressive ascites and ischemia of intestine due to microthrombi propagation of blood vessels. Intestinal suffusion secondary to acute portal hypertension can also be present.</p>
      </sec>
      <sec id="article-31049.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation of DVT includes blood tests to help stratify patients with the risk for deep venous thrombosis (DVT) include D-dimer assay; levels of antithrombin III (ATIII),&#x000a0;N-terminal pro-brain natriuretic peptide (NT-proBNP), and C-reactive protein (CRP); and erythrocyte sedimentation rate (ESR). Studies have shown all patient presenting with a positive D-dimer and leg swelling&#x000a0;have confirmed DVT on evaluation.<xref ref-type="bibr" rid="article-31049.r11">[11]</xref></p>
        <p>Radiologic investigations include an ultrasound of the affected leg and pelvis. It may require additional evaluation in some patients with either CT (computed tomography) scan or MRI (magnetic resonance imaging).</p>
        <p>Investigation for portal vein thrombosis includes laboratory test: coagulation studies to rule out inherited coagulation disorders, liver function test, and radiographic imaging. Ultrasound is the first line modality, and this can be done endoscopically. Further imaging modalities are MRI or MRA and possible CT scan.</p>
      </sec>
      <sec id="article-31049.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of VTE is to prevent further extension of DVT proximally and the prevention of pulmonary embolism. Treatment&#x000a0;is divided into an initial active treatment phase of 3 months and a subsequent secondary phase.<xref ref-type="bibr" rid="article-31049.r12">[12]</xref>&#x000a0;Anticoagulation during the initial treatment shows a reduction in&#x000a0;the risk of embolization in patients with proximal DVT or PE and reduces the risk of death in patients with PE.<xref ref-type="bibr" rid="article-31049.r13">[13]</xref></p>
        <p>Initial treatment consists of the administration of an anticoagulant. Anticoagulants include low molecular weight heparin (LMWH) or fondaparinux or unfractionated heparin (UFH) for a minimum of&#x000a0;5 days, with early administration of a vitamin-K antagonist (VKA) like warfarin.<xref ref-type="bibr" rid="article-31049.r14">[14]</xref>&#x000a0;An international normalized ratio (INR) of at least 2&#x000a0;is&#x000a0;achieved on 2 consecutive days, because of the slow onset of action of the antithrombotic effect of VKAs.<xref ref-type="bibr" rid="article-31049.r15">[15]</xref>&#x000a0;After the first&#x000a0;3&#x000a0;months,&#x000a0;management is based on the risk of bleeding compared to the risk of recurrent thrombosis. Thrombectomy of venous obstruction is less frequently performed, and often, an IVC filter is placed in patients in whom anticoagulation is contraindicated.</p>
        <p>Treatment for portal venous obstruction includes thrombolysis using tissue-type plasminogen activator (tPA) through the transhepatic route, followed by prolonged anticoagulation therapy with warfarin for at least 3 months.</p>
      </sec>
      <sec id="article-31049.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Venous thromboembolism: Trauma, edema, cellulitis</p>
          </list-item>
          <list-item>
            <p>Portal vein obstruction: Cirrhosis, Budd-Chiari, sarcoidosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31049.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>If treated appropriately, the overall prognosis of VTE is good.&#x000a0;</p>
        <p>The overall mortality has been reported to be less than 10% in&#x000a0;chronic pulmonary vein thrombosis.<xref ref-type="bibr" rid="article-31049.r16">[16]</xref></p>
      </sec>
      <sec id="article-31049.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complication of VTE is pulmonary embolism of the pulmonary artery which can lead to death.&#x000a0;</p>
        <p>Portal vein thrombosis complications include splenomegaly, esophageal- and gastric varices with or without bleeding, portal hypertensive gastropathy, and ascites.&#x000a0;</p>
      </sec>
      <sec id="article-31049.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Veins in almost any organ can be thrombosed or occluded. In many cases, because of collateral formation, symptoms do not occur immediately. However, the problem with vein thrombosis is the potential for the clot to embolize. Each year thousands of patients die from a pulmonary embolism, and in most cases, the cause is an embolic blood clot from the extremities. Healthcare workers including nurse practitioners must be aware of the complications of vein obstruction, particularly in the leg and pelvic veins, central neck veins, hepatic veins,&#x000a0;and the superior mesenteric veins. In many cases, a duplex ultrasound will reveal the vein obstruction, and appropriate&#x000a0;patient referral is necessary.</p>
      </sec>
      <sec id="article-31049.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31049&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31049">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/vein-obstruction/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31049">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31049/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31049">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31049.s14">
        <title>References</title>
        <ref id="article-31049.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirmerova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Seidlerova</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Subrt</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>The association of factor V Leiden with various clinical patterns of venous thromboembolism-the factor V Leiden paradox.</article-title>
            <source>QJM</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>107</volume>
            <issue>9</issue>
            <fpage>715</fpage>
            <page-range>715-20</page-range>
            <pub-id pub-id-type="pmid">24633260</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Venous thromboembolism in pregnancy.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>326</fpage>
            <page-range>326-31</page-range>
            <pub-id pub-id-type="pmid">19228606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tapson</surname>
                <given-names>VF</given-names>
              </name>
            </person-group>
            <article-title>The role of smoking in coagulation and thromboembolism in chronic obstructive pulmonary disease.</article-title>
            <source>Proc Am Thorac Soc</source>
            <year>2005</year>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-7</page-range>
            <pub-id pub-id-type="pmid">16113472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Staercke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>WC</given-names>
              </name>
            </person-group>
            <article-title>The effects of obesity on venous thromboembolism: A review.</article-title>
            <source>Open J Prev Med</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>2</volume>
            <issue>4</issue>
            <fpage>499</fpage>
            <page-range>499-509</page-range>
            <pub-id pub-id-type="pmid">26236563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Zayaruzny</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Heit</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Fidan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism.</article-title>
            <source>Am J Hematol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>82</volume>
            <issue>9</issue>
            <fpage>777</fpage>
            <page-range>777-82</page-range>
            <pub-id pub-id-type="pmid">17626254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinjala</surname>
                <given-names>R</given-names>
              </name>
              <collab>ENDORSE-India investigators</collab>
            </person-group>
            <article-title>Venous thromboembolism risk &#x00026; prophylaxis in the acute hospital care setting (ENDORSE), a multinational cross-sectional study: results from the Indian subset data.</article-title>
            <source>Indian J Med Res</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>136</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-7</page-range>
            <pub-id pub-id-type="pmid">22885265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woller</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Aston</surname>
                <given-names>VT</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients.</article-title>
            <source>Am J Med</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>124</volume>
            <issue>10</issue>
            <fpage>947</fpage>
            <page-range>947-954.e2</page-range>
            <pub-id pub-id-type="pmid">21962315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spencer</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Lessard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Venous thromboembolism in the outpatient setting.</article-title>
            <source>Arch Intern Med</source>
            <year>2007</year>
            <month>Jul</month>
            <day>23</day>
            <volume>167</volume>
            <issue>14</issue>
            <fpage>1471</fpage>
            <page-range>1471-5</page-range>
            <pub-id pub-id-type="pmid">17646600</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spencer</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lessard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Emery</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gore</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pacifico</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Weitz</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Factors associated with adverse outcomes in outpatients presenting with pulmonary embolism: the Worcester Venous Thromboembolism Study.</article-title>
            <source>Circ Cardiovasc Qual Outcomes</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>390</fpage>
            <page-range>390-4</page-range>
            <pub-id pub-id-type="pmid">20606125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Esmon</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Basic mechanisms and pathogenesis of venous thrombosis.</article-title>
            <source>Blood Rev</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>225</fpage>
            <page-range>225-9</page-range>
            <pub-id pub-id-type="pmid">19683659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johanning</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Elmore</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>D-dimer and calf circumference in the evaluation of outpatient deep venous thrombosis.</article-title>
            <source>J Vasc Surg</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>877</fpage>
            <page-range>877-80</page-range>
            <pub-id pub-id-type="pmid">12422095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kearon</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A conceptual framework for two phases of anticoagulant treatment of venous thromboembolism.</article-title>
            <source>J Thromb Haemost</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>507</fpage>
            <page-range>507-11</page-range>
            <pub-id pub-id-type="pmid">22497864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>BARRITT</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>JORDAN</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial.</article-title>
            <source>Lancet</source>
            <year>1960</year>
            <month>Jun</month>
            <day>18</day>
            <volume>1</volume>
            <issue>7138</issue>
            <fpage>1309</fpage>
            <page-range>1309-12</page-range>
            <pub-id pub-id-type="pmid">13797091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kearon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Akl</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Comerota</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Prandoni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bounameaux</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Goldhaber</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Dentali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Crowther</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kahn</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</article-title>
            <source>Chest</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2 Suppl</issue>
            <fpage>e419S</fpage>
            <page-range>e419S-e496S</page-range>
            <pub-id pub-id-type="pmid">22315268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perrier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stavros</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Giancarlo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nazzareno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pruszczyk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Frank</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Uwe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Walter</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Remy-Jardin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bassand</surname>
                <given-names>JP</given-names>
              </name>
              <collab>Task Force per la Diagnosi e il Trattamento dell'Embolia Polmonare Acuta della Societ&#x000e0; Europea di Cardiologia</collab>
            </person-group>
            <article-title>[Guidelines on the diagnosis and management of acute pulmonary embolism].</article-title>
            <source>G Ital Cardiol (Rome)</source>
            <year>2009</year>
            <month>May</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-47</page-range>
            <pub-id pub-id-type="pmid">19537442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31049.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ponziani</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Zocco</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Campanale</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rinninella</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tortora</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Maurizio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bombardieri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Cristofaro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>De Gaetano</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Landolfi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gasbarrini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Portal vein thrombosis: insight into physiopathology, diagnosis, and treatment.</article-title>
            <source>World J Gastroenterol</source>
            <year>2010</year>
            <month>Jan</month>
            <day>14</day>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>143</fpage>
            <page-range>143-55</page-range>
            <pub-id pub-id-type="pmid">20066733</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
